News
1 aug. 2024
Aplex Bio is pleased to welcome biotech veteran Rolf Ehrnström to its Board, bolstering leadership as the company advances in the molecular testing market.
Stockholm, 26 Aug 2024 – Aplex Bio is pleased to announce the appointment of Rolf Ehrnström to its Board of Directors. Rolf brings a wealth of experience from biotech and diagnostic companies and will provide valuable insights as Aplex Bio continues to execute its strategic vision and grow its presence in the molecular testing space.
“We are thrilled to welcome Rolf Ehrnström to our Board of Directors” said Umear Naseem, Founder & CEO.
Rolf’s extensive background with companies like Amersham Pharmacia Biotech, Dako (acquired by Agilent), and the microfluidics pioneer company Gyros, along with their proven track record of success, will be instrumental as Aplex Bio continues to drive innovation and deliver value to our shareholders. Rolf also holds board seats at Gradientech AB, Lynsight Oy, Scandinavian Chemotech AB, and Fluimedix A/S.
“I am honored to join the Board of Directors at Aplex Bio,” said Rolf Ehrnström. “I look forward to working with my fellow board members and the management team to help shape the future of the company during this exciting time of growth and opportunity.”
Rolf’s appointment reflects Aplex Bio’s commitment to strengthening its leadership team and fostering a diverse, dynamic, and experienced board that will guide the company toward continued success.
About Aplex Bio
Aplex Bio, a Swedish start-up company founded in 2020, is developing and commercializing a next-generation Hyperplex PCR™ technology enabling analysis of 100+ target in a single tube. The technology enables applications from research to in-vitro diagnostics (IVD) and precision diagnostics. Aplex Bio is based in Stockholm at the Karolinska Institute (KI) campus and is part of KI Innovations.
Contact
Umear Naseem, CEO and Founder, Aplex Bio